COMPANY STATEMENT OF CHANGES IN EQUITY for the year ended 31 December 2017 Share-based Share Share Merger payment Retained capital premium reserve reserve earnings Total equity m m m m m m At 31 March 2016 0.1 101.6 131.9 17.4 49.1 300.1 Loss for the period 10.6 10.6 Skyepharma scheme of arrangement 0.1 424.3 424.4 Merger relief 2.0 2.0 Share transaction costs 2.5 2.5 Employee share transactions 0.7 2.3 1.1 1.9 Transfers within reserves 13.9 13.9 At 31 December 2016 0.2 102.3 551.7 5.8 53.3 713.3 Profit for the year note 2 16.1 16.1 Employee share transactions 0.5 3.9 1.8 2.6 Share buyback and cancellation programme 1.4 1.4 Transfers within reserves 1.3 1.3 At 31 December 2017 0.2 102.8 551.7 8.4 67.5 730.6 The profit for the year ended 31 December 2017 was 16.1m 2016: loss 10.6m, which included 29.0m 2016: nil of dividend income fromsubsidiary undertakings.
The accompanying notes form an integral part of these Company financial statements prepared under FRS 101 .
152 Vectura Group plc Annual Report and Accounts 2017
